Apr. 14, 2026
New Blood Test Aims to Detect Lung Cancer Years Earlier
Emerging technologies could increase screening by providing a simpler initial step before imaging.
Apr. 14, 2026
Cellectar Enrolls First Patient in CLR 125 Clinical Trial for Refractory Triple Negative Breast Cancer
Study will evaluate tumor-specific uptake, safety, tolerability, and preliminary efficacy of CLR 125 radioconjugate in TNBC patients
Apr. 14, 2026
Cellectar Enrolls First Patient in CLR 125 Clinical Trial for Triple Negative Breast Cancer
The Phase 1b trial will evaluate the company's Auger-emitting radioconjugate for refractory TNBC patients.